MAPT and Alzheimer disease: For example, in neurodegenerative diseases such as Parkinson’s disease (PD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA), Alzheimer’s disease (AD), and Huntington’s disease, disease-associated proteins (e.g., alpha-synuclein (aSyn), amyloid-β, tau, or huntingtin) aggregate into β-sheet-rich structures that are thought to be toxic to cells (Soto, 2003; Goedert, 2015; Bates, 2003; Taylor et al, 2002; Ross and Poirier, 2004).